IRVINE, CA, January 19, 2010 -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today that the Federal Patent Court in Munich, Germany, has upheld the validity of Edwards' German Andersen patent for transcatheter valve technology. Edwards succeeded in having CoreValve's invalidity claims dismissed on all grounds.

"We are very pleased that Edwards' Andersen patent has again been upheld, as it was last year in the United Kingdom," said Larry L. Wood, Edwards' corporate vice president, transcatheter valve replacement.

Today's decision resulted from a counter-suit filed by CoreValve in response to the patent infringement case filed by Edwards in Germany in May 2007.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring, with more than five decades of experience in partnering with clinicians to develop life-saving innovations. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company's global brands include Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, Magna, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.